Background: The N parameter in the tumor-node-metastasis (TNM) classification of lung cancer is categorized according to the location of nodal metastasis, while that for some other cancers are classified according to the size and number of metastatic foci. In lung cancer, the impact of size of nodal metastasis on prognosis is unclear. This analysis aims to examine whether it is possible to subdivide the pathological N (pN) factor based on the tumor diameter of lymph node metastases.
Methods: We studied 35 cases of adenocarcinoma and 26 cases of squamous cell carcinoma of the lung. The maximum diameter of lymph node metastasis was measured, and the relationship between the maximum diameter of lymph node metastases and prognosis was investigated.
Results: Squamous cell carcinoma cases had a significantly larger maximum tumor diameter of lymph node metastasis than adenocarcinoma cases (P=0.03). Based on receiver operating characteristic (ROC) curve results for the adenocarcinoma cases, we set 4 mm as a diameter cutoff value. The 5-year overall survival (OS) rate was 85.6% for patients with diameters ≤4 mm and 57.7% for those with diameters >4 mm; this difference was statistically significant (P=0.04). On univariate analysis using a Cox proportional hazards model, significant differences were observed in metastatic lymph node diameter (≤4 >4 mm) (P=0.04), sex (P=0.04), and pathological T (pT) status (pT1 and 2 pT3 and 4) (P=0.03). However, similar results were not obtained for patients with squamous cell carcinoma.
Conclusions: The tumor diameter of pathological N1 lymph node metastases impacts the prognosis of patients with lung adenocarcinoma. If pathological N1 can be further subdivided according to tumor diameter of lymph node metastases, a more accurate prognosis may become possible. However, pathological type must be considered for staging in lung cancer. While the pN parameter for most cancers considers tumor size of lymph node metastasis, this does not apply to lung cancer.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11494580 | PMC |
| http://dx.doi.org/10.21037/jtd-24-792 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Defective removal of invariant chain peptides from MHC class II suppresses tumor antigen presentation and promotes tumor growth.
Cell Rep
January 2025
Experimental Immunology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892, USA. Electronic address:
Tumor-draining lymph node dendritic cells (DCs) are poor stimulators of tumor antigen-specific CD4 T cells; however, the mechanism behind this defect is unclear. We now show that, in tumor-draining lymph node DCs, a large proportion of major histocompatibility complex class II (MHC-II) molecules retains the class II-associated invariant chain peptide (CLIP) fragment of the invariant chain bound to the MHC-II peptide binding groove due to reduced expression of the peptide editor H2-M and enhanced activity of the CLIP-generating proteinase cathepsin S. The net effect of this is that MHC-II molecules are unable to efficiently bind antigenic peptides.
View Article and Find Full Text PDFRare Cutaneous Primary Presentation of Extracavitary Primary Effusion Lymphoma.
Am J Dermatopathol
January 2025
Department of Dermatology, Columbia University Medical Center, New York, NY; and.
Primary effusion lymphoma (PEL) is a rare and aggressive B-cell lymphoma typically associated with human herpesvirus 8 (HHV-8) and Epstein-Barr virus infections. It classically presents as a malignant effusion in body cavities, but rarely presents with an extracavitary variant characterized by solid tumors in lymph nodes or extranodal sites such as the gastrointestinal tract, skin, lungs, and nervous system. This case report describes an unusual presentation of primary cutaneous extracavitary PEL in an HIV-positive patient that has only been reported in 8 cases previously.
View Article and Find Full Text PDFMetastatic sites of baseline as predictors in recurrent or metastatic nasopharyngeal carinoma treated with PD-L1 inhibitor: a secondary analysis of multicenter, single-arm, phase II study (KL-A167).
Cancer Immunol Immunother
January 2025
Department of Biotherapy, Cancer Center, West China Hospital, Sichuan University, No. 37 Guo Xue Alley, Sichuan, 610041, Chengdu, China.
Background: Immune checkpoint inhibitors (ICIs) show optimal treatment effects on recurrent or metastatic nasopharyngeal carcinoma(R/M NPC). Nonetheless, whether metastatic sites impact ICIs efficacy remains unclear.
Methods: We performed a secondary analysis of R/M NPC patients treated with KL-A167, a programmed cell death-ligand 1(PD-L1) inhibitor, based on a multicenter, single-arm, phase II study from China between 2019 and 2021 years, which represents the first and most comprehensive analysis of the effectiveness of a PD-L1 inhibitor in patients who have been previously treated.
Feasibility and impact of sentinel lymph node biopsy in patients affected by ano-rectal melanoma.
Tech Coloproctol
January 2025
Department of Surgical Sciences, University of Turin, Turin, Italy.
Introduction: Anorectal melanoma (ARM) is rare and highly lethal neoplasm. It has a poorer prognosis compared with cutaneous ones. Sentinel lymph node biopsy (SLNB) has become the preferred method of nodal staging method for cutaneous melanoma.
View Article and Find Full Text PDFPrognostic relevance of CD163 immune cells in patients with metastatic breast cancer.
Cancer Immunol Immunother
January 2025
Department of Clinical Sciences Lund, Division of Oncology, Lund University, 221 84, Lund, Sweden.
Metastatic breast cancer (MBC) is generally considered an incurable disease and even though new treatments are available, the median survival is approximately three years. The introduction of immune therapies for MBC highlights the importance of the immune system in cancer progression and treatment. CD163 anti-inflammatory myeloid cells, including tumor associated macrophages (TAMs), are known to be of relevance in early breast cancer but their role in MBC is not yet established.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!